Introduction
Fas ligand (FasL, CD95L, APO-1L) is a type II transmembrane protein of the tumor necrosis factor family that induces apoptosis in Fas-positive cells. [1] [2] [3] It is predominantly expressed in activated T cells and it is one of the effector molecules for cytotoxic T lymphocyte (CTL) and NK cell-induced apoptosis. [4] [5] [6] Mice and humans, with a defect in Fas expression or function demonstrate a profound lymphoaccumulative disorder together with ageassociated autoimmune phenomena. [7] [8] [9] Mutation of FasL gene in mice resulted in similar phenotype (gld-generalized lymphoproliferative disease). 10 This suggests that the Fas/FasL system plays an important role in the maintenance of immune homeostasis. 11, 12 Sertoli cells in the testis and epithelial cells in the anterior chamber of the eye also express FasL. [13] [14] [15] The presence of FasL confers immunological privilege to these cells and allo-or xenografts transplanted into these sites are not rejected since FasL expressed by Sertoli cells and epithelial cells of the anterior chamber of the eye induce death of infiltrating T cells expressing high levels of Fas. 15 Lau and co-workers 16 reported that syngenic myoblasts engineered to express FasL could delay rejection of pancreatic islet allografts when transplanted under the kidney capsule. Recently, expression of FasL was found on some tumor cells such as melanoma, colon
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Received 8 May 1998; accepted 30 June 1998 cancer cells or hepatocellular carcinoma cells and these FasL-expressing tumor cells were capable of inducing apoptosis of lymphocytes, suggesting that this might be an additional mechanism for malignant cells to escape immunosurveillance. [17] [18] [19] [20] On the other hand, it was shown that the presence of FasL can involve destruction of FasL-bearing cells. First, Seino et al 21 showed that introduction of FasL cDNA into murine tumor cells did not affect growth in vitro but caused rejection in vivo. Further, Kang et al 22 reported that transplantation of islets of Langerhans infected with an adenoviral vector containing FasL into allogenic diabetic hosts underwent accelerated rejection. Transgenic expression of CD95 ligand on islet ␤ cells induced a granulocytic infiltration but did not confer immune privilege upon islet allografts. 23 The authors demonstrated that this type of rejection was T cell and B cell independent and was mediated mainly by neutrophils, which involved local inflammation with further destruction of neighboring tissues. Until now it has not been known why the presence of FasL on the surface of cells can confer a state of immune privilege in some settings while in others it may precipitate inflammation and cell destruction. 24, 25 The current study was undertaken to analyze whether allogenic fibroblasts engineered to express FasL could abrogate tumorigenicity and induce specific immune response to tumor antigens in a murine animal model. Transfected cells were selected in geneticin-containing medium and 10 colonies from both transfections were obtained for screening of FasL expression. Among these colonies, we selected one colony from pCl/FasL transfection which expressed a high level of FasL (PA317/FasL) and one colony from pClneo transfection (lacking FasL expression) was taken as a control (PA317/Contr) (see Figure 1a ). As shown in Figure 1b growth rate (as estimated by incorporation of 3 H-TdR) was similar for PA317/FasL and PA317/Contr at different densities of cells.
To assess the function of FasL in transfected cells, we incubated PA317/FasL or PA317/Contr with YAC-1 cells. These cells are Fas positive and have been used in other studies as target cells for Fas/FasL interaction. 16 As shown in Figure 2b , PA317/FasL killed YAC-1 cells in a dose-dependent manner. We observed 31.2, 54.1, 58.9 and 69.3% YAC-1 cell death when effector cells were cocultured with target cells at effector/target ratios of 0.2:1, 0.6:1, 2:1 and 6:1, respectively. In contrast, PA317/Contr (Table 1 ). In these animals the incidence of tumors as well as tumor growth rate increased as the proportion of PA317/FasL cells decreased (data not shown).
In a separate set of experiments we observed that, similarly to what was found with BNL cells, only one of eight animals developed a tumor when they received CT26 cells mixed with PA317/FasL at a 1:1 ratio. However, all eight animals developed tumors when they were given CT26 cells mixed with PA317/Contr cells at same ratio (Table 1) .
In order to identify the effector cells involved in the Table 2 ). In studies aimed at analyzing long-term protection, we found that 50% of mice immunized with BNL and PA317/FasL still exhibited protection against rechallenge with BNL cells 100 days after immunization (Table 2) .
A specific antitumoral protective effect was also 
Figure 4 Histological examination of the tumor implantation sites. Inflammatory response with predominance of polymorphonuclear neutrophils (thick short black arrows) and mononuclear cells (thin black arrows) in the infiltrate was observed in mice injected with BNL mixed with PA317/FasL cells on day 1 after inoculation. Among inflammatory cells cellular debris was seen (white arrows) (a). Massive infiltration of polymorphonuclear neutrophils and mononuclear cells was present at the site of injection of BNL cells mixed with PA317/FasL at day 4 (b). High magnification field showing polymorphonuclear neutrophils on day 4 in mice injected with BNL plus PA317/FasL (c). A cluster of BNL cells (below black stars) is surrounded by a rim of mild inflammatory reaction with a few neutrophils and mononuclear cells in animals inoculated with BNL cells mixed with PA317/Contr cells at day 1 after inoculation of the cell mixture (d

respectively). Depletion of CD8
+ lymphocytes was associated with appearance of tumors in all rechallenged animals, whereas in animals given monoclonal antibodies anti-CD4 + no tumor formation was observed (Table 3 ).
In vivo treatment of established tumor with PA317/FasL
In order to know whether antitumoral immunity induced by PA317/FasL could eliminate established BNL tumors, we treated established s.c. tumor (0.5 cm in diameter) by intratumor injection of PA317/FasL cells or by injection of a mixture of BNL and PA317/FasL cells at a distal site. Figure 5a shows that intratumor injection of 5 × 10 6 of PA317/FasL to previously established BNL tumors did not affect the growth of the tumors as compared with tumors injected with 5 × 10 6 PA317/Contr. In addition, we observed no differences in survival of tumor-bearing mice treated with intratumoral injection of either PA317/FasL or PA317/Contr (Figure 5b) .
Injection of the mixture of PA317/FasL and BNL (5 × 10 6 and 5 × 10 6 ) cells to animals with previously established BNL tumors (0.5 cm in diameter) in the con- 
Discussion
13-18 Allogenic CT26 colon carcinoma cells expressing mouse FasL markedly reduced allogenic cytotoxic T lymphocytes and completely inhibited generation of alloantibodies of both IgM and IgG subclasses. 26 In contrast with these experimental findings, the presence of FasL on the surface of allogenic pancreatic islets failed to protect these islets from allogenic rejection and this reaction was found to involve the formation of a granulocytic infiltrate. 22 Introduction of human or mouse FasL cDNA into murine tumor cells did not affect tumor growth in vitro but caused rejection of the tumor by infiltrating neutrophils with subsequent induction of tumorspecific protective immunity. 21 More recent data indicate that adenovirus-mediated gene transfer of mouse FasL induced tumor regression in animal models implanted with Fas-positive and -negative tumor cells. 27 In the light of the above data we decided to study whether allogenic fibroblasts engineered to express FasL are able to abolish tumorigenicity and induce tumorspecific protective immunity. We decided to transduce allogenic fibroblasts stably instead of syngenic cells because transduction with FasL of syngenic cells entails the risk of inducing a state of immunoprivilege. 16 Human FasL gene was chosen because of its ability to be functional in the soluble form, which could potentiate local inflammatory response, whereas mouse FasL loses its activity when it is cleaved from the membrane. 28 Furthermore, recombinant soluble human FasL is directly chemotactic for mouse neutrophils in vitro. From the practical point of view, allogenic fibroblasts with functional FasL seem to be more useful when thinking in terms of potential applications for treatment of tumors in humans, as allogenic fibroblasts can be easily prepared in large quantities. These cells can be mixed with irradiated tumor cells obtained from the patient and inoculated to induce a specific antitumoral immunity. When thinking in terms of practical applications, our strategy offers advantages in respect of the use of adenoviral vectors expressing Fas ligand, which can induce severe liver toxicity since hepatocytes express Fas constitutively 29 and also in respect of procedures based on direct transduction of tumor cells with Fas ligand since it is difficult to culture tumor cells from specific patients.
Our results show that fibroblasts engineered to express FasL and their supernatant were able to induce apoptosis 
(ANOVA test). (b) Survival of animals after treatment. Significant prolongation of survival was found in animals treated by contralateral vaccination with BNL+PA317/FasL as compared with BNL+PA317/Contr. P Ͻ 0.01 (log rank test).
of Fas-bearing YAC-1 cells. Although PA317/FasL did not induce toxic effects on BNL or CT26 tumor cells in vitro, these tumor cells lose their tumorigenicity when they are implanted into syngenic mice together with PA317/FasL cells. This observation suggests that PA317/FasL cells trigger in vivo mechanisms responsible for tumor suppression. It has been shown that some cytokines such as tumor necrosis factor (TNF), even if they have no direct action on the target tumor cells in vitro, can induce antitumor reaction in vivo by potentiating nonspecific and/or specific host responses against tumors. 30, 31 In our study, histologic examination of the site of implantation revealed the presence of a dense infiltration of neutrophils and mononuclear cells with disappearance of tumor cells in animals which received the mixture of tumor cells and PA317/FasL. In contrast, mice treated with BNL cells mixed with PA317/Contr exhibited progressive growth of neoplastic cells with formation of a tumor nodule surrounded by only a mild inflammatory reaction. This observation, which is similar to observations in previous reports using FasL-expressing tumor cells, 21 suggests that activation of neutrophils is a basic mechanism involved in tumor elimination in the system utilized in the present work.
Importantly, we observed that no tumor occurred after contralateral rechallenge with BNL cells in animals treated with BNL and PA317/FasL 14 days before. In contrast neoplastic growth developed in the same group of animals after rechallenge with a tumor cell line different from that used for immunization. These data point to a specific antitumoral immune response induced by treatment with a mixture of neoplastic cells and PA317/FasL cells. One hundred days after priming with a BNL and PA 317/FasL cell mixture 50% of animals still manifested protection. This effect appears to be due to the induction cytotoxic T cells since depletion of CD8 + T cells abrogated the protection against tumor formation. Our unpublished data and reports in the literature 32 indicate that both BNL and CT26 are poorly immunogenic and express low levels of MHC class I antigens and no class II molecules. Thus, in accordance with previous studies, 21, 27 our findings support the idea that immunity induced by FasL against tumors seems not to depend on the immunogenicity of the malignant cells. In our study no antineoplastic effect was observed by injecting PA317/FasL intratumorally. Different reasons might account for this lack of antitumoral effect: first, it may be possible that the viability of allogenic cells injected into the solid tumor nodule might not be good enough to cause biological effects; and second, the immunosuppressive microenvironment within an established tumor 33 might prevent neutrophil recruitment and the induction of an effective antitumoral immunity.
Interestingly, however, contralateral vaccination of animals with previously established BNL tumors with a mixture of BNL cells and PA317/FasL resulted in decreased tumor growth rate and in prolongation of animal survival, as compared with animals given BNL and PA317/Contr. These results indicate that treatment of animals with a mixture of BNL and PA317/FasL cells was able to induce immune responses which can not only eliminate tumor cells after rechallenge but also significantly inhibit the growth of pre-established tumors. This finding has important implications for the delineation of antitumoral strategies in humans aimed at preventing recurrence after surgical resection of neoplasms or at eliminating residual cancer cells after surgical removal of main, large tumors. These aims could be accomplished by vaccination of the patient after surgery using allogenic fibroblasts engineered to express FasL and irradiated tumor cells obtained at surgery from the same patient.
In summary, our data demonstrate that allogenic cells engineered with FasL are able to abrogate tumorigenicity of tumor cells in vivo by recruiting inflammatory cells. Allogenic fibroblasts expressing FasL are useful for antitumoral vaccination when administered in mixtures with syngenic tumor cells. This procedure protects against rechallenge with neoplastic cells and inhibits growth of established tumors by eliciting a specific antitumor immune response. These data suggest that local expression of FasL can be used as a tool for immunotherapy of cancer.
Materials and methods
Animals, cell culture and reagents Six-to eight-week-old Balb/c female mice were used in the study. They were purchased from Charles River (Barcelona, Spain). During the experimental period animals were housed under standard conditions. Methylcholanthrene epoxide-transformed mouse liver cell line BNL 1ME A.7R.1 (BNL) from Balb/c mouse, YAC-1 mouse lymphoma cell line and PA317 mouse fibroblast cells from Swiss mouse were obtained from American Type Cell Collection (ATCC, Rockville, MD, USA). Colon cancer (CT26) cell line from Balb/c mouse was a kind gift from Dr K Brand, Max-Planck-Institut fur Biochemie (Germany). The cell lines were cultured at 37°C, 5% CO 2 in DMEM (BNL, PA317) or RPMI 1640 (CT26, YAC-1) medium supplemented with 10% fetal calf serum, 2 mm l-glutamine and penicillin/streptomycin. All media and supplements were from Biological Industries (Kibbutz Beit Haemek, Israel) and BioWhittaker (Vervier, Belgium).
Plasmid construction
The human Fas ligand (FasL) cDNA was released from pBX-hFL1 plasmid 1 (a kind gift from S Nagata) by XbaI cutting and was cloned into the XbaI site of pCl/neo eukaryotic expression vector plasmid (obtained from Promega, Madison, MI, USA). The obtained plasmid included FasL gene under control of the CMV promoter together with the linked dominant biochemical selection marker gene neomycin, a geneticin-resistance gene driven by simian virus 40 (SV40) promoter, allowing the selection of transfected cells in geneticin-containing medium. The orientation of FasL insert relative to promoter was confirmed by enzyme digestion.
Stable transfection
A newly created plasmid (pCl/FasL) or an empty plasmid (pCl/neo) were transfected into PA317 fibroblast cell line using calcium phosphate transfection method. Briefly, the 1 × 10 5 PA317 cells were seeded per well of six-well plate. On the next day, cells were transfected with 10 g of plasmid DNA for 16 h. Two days after transfection, cells were cultured in geneticin (G418)-containing medium (GibcoBRL, Barcelona, Spain) at a concentration of 800 g/ml for 2 weeks. Approximately 10-15 colonies from each transfection were picked up for screening of FasL expression. One colony from pCl/FasL transfection that expressed high levels of FasL and another from pCl/neo transfection that did not express FasL were chosen for further studies and were designated as PA317/FasL and PA317/Contr.
RNA isolation and RT-PCR
To identify clones with stable expression of FasL, total RNA was isolated from all colonies using commercial kit Ultraspec RNA (Biotex, Houston, TX, USA). For RT-PCR, cDNA was synthesized from 1 g of total RNA in 10 l of volume using M-MuLV reverse transcriptase. PCR amplification was performed with 4.8 l cDNA, 100 pmol each of oligonucleotide primer, 200 mm dNTP, 3 mm MgCl 2 , and 2.5 units Taq polymerase in PCR buffer (Biotaq; Ecogen, Barcelona, Spain) in a total volume of 50 l for 30 cycles. Each cycle included denaturation at 94°C for 1 min, annealing at 60°C for 1 min, and primer extension at 72°C for 1 min. The sense and antisense PCR primers for human FasL gene used were CAGCTCTTCCACCTACAGAAGG (5′ to 3′, nt 371-392 corresponding to published sequence from GenBank accession no. U11821) and CAAAATTGACCAGAGA-GAGCTC (5′ to 3′, nt 872-851). 502 bp of FasL fragment was obtained after PCR amplification. As a control we used amplification of the ␤-actin gene. 34 To analyze Fas expression in BNL and CT26 cells we used 1 g of total RNA for reverse transcription, followed by amplification using mouse Fas primers in above conditions for 30 cycles. The sense and antisense PCR primers for mouse Fas gene used were GCTGGCTCACAGTTAAGAGT (5′ to 3′, nt 86-105 corresponding to the published sequence) 35 and CAACCATAGGCGATTTCTGG (5′ to 3′, nt 565-546). 480 bp of Fas fragment was obtained after PCR amplification.
To measure the growing rate of PA317/FasL and PA317/Contr, cells were seeded in triplicate in a 96-well dish at 1 × 10 3 , 5 × 10 3 , 1 × 10 4 cells per well for 48 h and then were labeled with 3 H-TdR (methyl-were harvested and measurement as well as calculation was given as above.
Assessment of DNA fragmentation in target cells
The function of Fas ligand in stably transfected PA317 cells was assessed by quantification of DNA fragmentation of target cells by the JAM test. 36 The adherent PA317/Fasl and PA317/Contr cells were seeded in triplicate into a flat-bottomed 96-well microtiter plate at 1 × 10 After coculture at 37°C for 8 h, the cells were removed from the wells by pipetting up and down five times and were collected by filtration on to glass fiber filters using a 96-well filtration unit. The cells were hypotonically lysed, and fragmented DNA was washed through the filter four times with 0.25 ml water. The radioactivity of intact chromosomal DNA retained on each filter was measured by liquid scintillation counting. Specific cell killing was calculated using the following equation: For analysis of DNA fragmentation by electrophoresis, 1 × 10 6 YAC-1 cells were cocultured in complete RPMI 1640 medium with a confluent monolayer of previously washed PA317/Fasl or PA317/Contr in 10-cm plates for 8 h. Then, floating YAC-1 cells were harvested, washed once and resuspended in lysing buffer (10 mm Tris/HCl pH 8.0; 10 mm EDTA; 0.5% Triton X). Tubes were then transferred to ice and the cells were lysed for 5 min. After centrifugation at 13 000 g, the supernatant was treated with 100 g/ml RNAse (Boehringer Mannheim, Penzberg, Germany) for 2 h at 37°C. Then, SDS and proteinase K (Sigma, St Louis, MO, USA) were added to a final concentration of 0.5% and 200 g/ml, respectively. The extracts were left for 2 h at 50°C, and subsequently supernatants were carefully collected. The low molecular weight DNA was extracted twice in phenol and phenol/chloroform, and ethanol precipitated. Finally, the DNA was resuspended in TE buffer and loaded on to 1.5% agarose gel. 2 ). Mice free of tumors 100 days after challenge were classified as survivors. Animals with tumors that exceeded 1.5 cm in two perpendicular diameters or 2.0 cm in one were killed for humanitarian reasons.
In vivo depletion of lymphocytes and tumor incidence L3T4 (CD4 + )-specific rat anti-mouse hybridoma GK1-5 and (CD8 + )-specific rat anti-mouse hybridoma H35.17.2 were used to obtain anti-CD4 + and anti-CD8 + antibodies. Ascitic fluid was obtained from nude mice pristaneprimed and injected with 10 6 hybridoma cells. Antibodies were prepared by precipitation with ammonium sulphate and dialyzed against phosphate-buffered saline. The protein concentration was assessed by measurement of the OD at 280 nm. Mice, three in each group, were depleted of CD4 + or CD8 + cells by i.p. injection of 300 g of anti-CD4 + or anti-CD8 + antibodies, 37 on days −3, −2, −1 and every 7 days for 50 days, following rechallenge with 5 × 10 6 BNL cells (this was done on day 0). On day −14 all animals were primed with the mixture of BNL cells and PA317/FasL at a ratio of 1:1 in the flank contralateral to that of the site of rechallenge. The efficiency of the depletion was assessed by flow cytometry on day 10.
Tumor growth incidence was assessed twice a week for 50 days.
Histological examination
Mice were inoculated subcutaneously with 5 × 10 6 BNL cells mixed with PA317/FasL or PA317/Contr cells at a ratio of 1:1. On days 1, 4 and 7, the inoculated site was dissected, fixed in 10% neutral-buffered formalin, and embedded in paraffin. Sections of 5 m were stained with hematoxylin and eosin.
